Today: 7 February 2026
Subscribe
Browse Category

Biotechnology News 1 January 2026 - 6 January 2026

Regencell Bioscience (RGC) stock jumps again: what to know behind the latest sharp swing

Regencell Bioscience (RGC) stock jumps again: what to know behind the latest sharp swing

Regencell Bioscience Holdings shares jumped 18.3% to $31.99 in midday Nasdaq trading Tuesday, after swinging between $26.60 and $34.40. No new company statements have been posted since its Oct. 31 annual report, which disclosed a DOJ trading probe and “substantial doubt” about its ability to continue as a going concern. About 850,000 shares changed hands.
6 January 2026
··
Wave Life Sciences stock jumps 17% as obesity gene-silencing race heats up

Wave Life Sciences stock jumps 17% as obesity gene-silencing race heats up

Wave Life Sciences shares surged 17.2% to $17.58 Tuesday on heavy volume, after new data from Arrowhead Pharmaceuticals showed weight loss benefits from RNAi obesity drugs. Wave is developing a similar therapy, WVE-007, targeting the same gene. The company recently raised $402.5 million in a public offering. Investors await further trial results expected in early 2026.
6 January 2026
··
Cyclerion Therapeutics stock jumps in premarket after Medsteer deal — what CYCN investors watch next

Cyclerion Therapeutics stock jumps in premarket after Medsteer deal — what CYCN investors watch next

Cyclerion Therapeutics shares surged 46% to $2.01 premarket Tuesday after announcing an expanded exclusive collaboration with Medsteer for its CYC-126 depression program. The company aims to start a Phase 2 proof-of-concept study in late 2026, with initial data expected in 2027. Cyclerion flagged “substantial doubt” about its ability to continue as a going concern and said it needs more funding.
6 January 2026
··
Thermo Fisher Scientific stock jumps as Evercore lifts target, with earnings in focus

Thermo Fisher Scientific stock jumps as Evercore lifts target, with earnings in focus

Thermo Fisher Scientific shares climbed 2.4% to $606.63 after Evercore ISI raised its price target to $650 and reaffirmed an “outperform” rating. The stock traded between $590 and $608.29 on volume of 1.6 million shares. Peers Danaher, Agilent, and Illumina also advanced. Investors await Thermo Fisher’s fourth-quarter results on Jan. 29 and updates on its planned $9.4 billion Clario acquisition.
5 January 2026
···
INBS stock drops today as Intelligent Bio Solutions’ $10M private placement puts dilution in focus

INBS stock drops today as Intelligent Bio Solutions’ $10M private placement puts dilution in focus

Intelligent Bio Solutions shares fell 12.1% to $8.38 in late morning trading after announcing a $10 million private placement with two tranches of warrants. The deal, priced at $4.35 per share and warrant, follows a manufacturing partnership with Syrma Johari MedTech aimed at cutting costs and boosting margins ahead of a planned 2026 U.S. launch.
2 January 2026
··
Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed

Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed

Cytokinetics shares closed up 3.5% at $63.54, ahead of the planned U.S. launch of Myqorzo for obstructive hypertrophic cardiomyopathy. EVP Andrew Callos sold 1,809 shares at $62.44 under a preset trading plan, retaining 51,353 shares. Investors await U.S. pricing, early prescription data, and a late February earnings update. Myqorzo carries a boxed warning and REMS safety requirements.
2 January 2026
·
CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics shares closed down 1.4% at $52.44 on Dec. 31, the final trading day of 2025. U.S. markets were shut Jan. 1 for New Year’s. Investors are watching for early-2026 updates on Casgevy’s rollout and the next earnings schedule as trading resumes Jan. 2. Biotech ETFs were little changed in light year-end trading.
2 January 2026
······
Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

Axsome Therapeutics shares surged 23% to $182.64 after the FDA accepted its supplemental application for AXS-05 in Alzheimer’s agitation and granted priority review. The stock traded on heavy volume, swinging between $148.79 and $184.40. Axsome also said its AXS-12 narcolepsy drug remains on track for a January 2026 filing. Markets will reopen Friday after the New Year’s Day holiday.
1 January 2026
···
Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

Cytokinetics shares closed 2025 up 3.5% at $63.54 after FDA cleared Myqorzo for obstructive hypertrophic cardiomyopathy. The drug, set to launch in January under a REMS program and boxed warning, will compete with Bristol Myers Squibb’s Camzyos. Chief Commercial Officer Andrew Callos sold 1,809 shares at $62.44 each on Dec. 29 under a pre-arranged plan. U.S. markets reopen Friday after the New Year’s holiday.
1 January 2026
····
Axsome stock jumps 23% after FDA sets April 30 deadline for Alzheimer’s agitation review

Axsome stock jumps 23% after FDA sets April 30 deadline for Alzheimer’s agitation review

Axsome Therapeutics shares surged 22.9% to $182.64 after the FDA granted priority review to its application for AXS-05 in treating agitation in Alzheimer’s disease, setting an April 30 decision date. The company also plans to file for approval of AXS-12 for cataplexy in narcolepsy this month, following supportive FDA meeting minutes. Trading volume reached 3.1 million shares.
1 January 2026
··
1 … 3 4 5 6 7 … 15

Stock Market Today

RTX stock faces Pentagon payout curb list next week as dividend stays in play

RTX stock faces Pentagon payout curb list next week as dividend stays in play

7 February 2026
RTX closed at $198.66 Friday, up 1.4%, after declaring a 68-cent quarterly dividend payable March 19. The Pentagon is expected to name defense contractors early next week that could face limits on dividends and buybacks under a Trump order. RTX’s Raytheon unit has been singled out as “least responsive.” Companies named would have 15 days to submit remediation plans.
Go toTop